KR102843438B1 - 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합 - Google Patents

암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합

Info

Publication number
KR102843438B1
KR102843438B1 KR1020247017968A KR20247017968A KR102843438B1 KR 102843438 B1 KR102843438 B1 KR 102843438B1 KR 1020247017968 A KR1020247017968 A KR 1020247017968A KR 20247017968 A KR20247017968 A KR 20247017968A KR 102843438 B1 KR102843438 B1 KR 102843438B1
Authority
KR
South Korea
Prior art keywords
regorafenib
limited
acid
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247017968A
Other languages
English (en)
Korean (ko)
Other versions
KR20240091188A (ko
Inventor
자비네 호프
라르스 뢰제
디터 초프
파비안 키쓸링
빌트루트 레데를레
데니스 돌레쉘
Original Assignee
바이엘 헬쓰케어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 헬쓰케어 엘엘씨 filed Critical 바이엘 헬쓰케어 엘엘씨
Publication of KR20240091188A publication Critical patent/KR20240091188A/ko
Application granted granted Critical
Publication of KR102843438B1 publication Critical patent/KR102843438B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247017968A 2017-06-02 2018-05-25 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합 Active KR102843438B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
EP17174169.7 2017-06-02
KR1020197038281A KR102673422B1 (ko) 2017-06-02 2018-05-25 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038281A Division KR102673422B1 (ko) 2017-06-02 2018-05-25 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합

Publications (2)

Publication Number Publication Date
KR20240091188A KR20240091188A (ko) 2024-06-21
KR102843438B1 true KR102843438B1 (ko) 2025-08-06

Family

ID=58992733

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197038281A Active KR102673422B1 (ko) 2017-06-02 2018-05-25 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합
KR1020247017968A Active KR102843438B1 (ko) 2017-06-02 2018-05-25 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197038281A Active KR102673422B1 (ko) 2017-06-02 2018-05-25 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합

Country Status (22)

Country Link
US (4) US11951166B2 (enExample)
EP (2) EP4342542A3 (enExample)
JP (3) JP7303122B2 (enExample)
KR (2) KR102673422B1 (enExample)
CN (3) CN117582495A (enExample)
AU (2) AU2018276273B2 (enExample)
BR (1) BR112019025478A8 (enExample)
CA (2) CA3244313A1 (enExample)
DK (1) DK3630112T3 (enExample)
ES (1) ES2978337T3 (enExample)
FI (1) FI3630112T3 (enExample)
HR (1) HRP20240551T1 (enExample)
HU (1) HUE066487T2 (enExample)
IL (2) IL317015A (enExample)
LT (1) LT3630112T (enExample)
MX (1) MX2023001721A (enExample)
PE (2) PE20200859A1 (enExample)
PL (1) PL3630112T3 (enExample)
PT (1) PT3630112T (enExample)
RS (1) RS65488B9 (enExample)
SI (1) SI3630112T1 (enExample)
WO (1) WO2018219807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066487T2 (hu) * 2017-06-02 2024-08-28 Bayer Healthcare Llc Regorafenib és nivolumab kombinációja rák kezelésére
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
WO2025117638A1 (en) * 2023-12-01 2025-06-05 Yale University Compositions and methods for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
WO2007054303A2 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
RS57875B1 (sr) 2012-09-25 2018-12-31 Bayer Pharma AG Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
EP3498734B1 (en) 2014-02-04 2021-09-01 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
US20170165364A1 (en) 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
CA2954508A1 (en) 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN107072984B (zh) 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
KR20170042778A (ko) * 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
EP3463456A1 (en) 2016-06-03 2019-04-10 ImClone LLC Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
HUE066487T2 (hu) * 2017-06-02 2024-08-28 Bayer Healthcare Llc Regorafenib és nivolumab kombinációja rák kezelésére
KR102692379B1 (ko) * 2017-06-05 2024-08-05 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Archives of pharmacal research, 2016, 39, 1577-1587
Digestive Diseases, 2016, 34(6), 714-730*

Also Published As

Publication number Publication date
CN117899212A (zh) 2024-04-19
HUE066487T2 (hu) 2024-08-28
US11517622B2 (en) 2022-12-06
DK3630112T3 (da) 2024-04-22
KR102673422B1 (ko) 2024-06-07
US20200155674A1 (en) 2020-05-21
FI3630112T3 (fi) 2024-05-02
RU2019143599A3 (enExample) 2021-09-10
CN110662540B (zh) 2024-01-26
CA3244313A1 (en) 2025-06-13
BR112019025478A2 (pt) 2020-06-23
US11951166B2 (en) 2024-04-09
EP4342542A2 (en) 2024-03-27
IL317015A (en) 2025-01-01
IL270948B1 (en) 2025-03-01
CA3065125C (en) 2025-06-10
US20200188372A1 (en) 2020-06-18
EP3630112A1 (en) 2020-04-08
MX2023001721A (es) 2023-02-22
SI3630112T1 (sl) 2024-06-28
US20220133888A1 (en) 2022-05-05
EP3630112B1 (en) 2024-01-31
IL270948A (en) 2020-01-30
IL270948B2 (en) 2025-07-01
RU2019143599A (ru) 2021-07-09
KR20200011971A (ko) 2020-02-04
CN117582495A (zh) 2024-02-23
AU2023282197B2 (en) 2025-06-26
ES2978337T3 (es) 2024-09-10
JP7303122B2 (ja) 2023-07-04
AU2018276273B2 (en) 2023-12-21
JP2020521786A (ja) 2020-07-27
KR20240091188A (ko) 2024-06-21
PL3630112T3 (pl) 2024-07-01
AU2023282197A1 (en) 2024-01-04
US20200179354A1 (en) 2020-06-11
PE20242220A1 (es) 2024-11-19
PT3630112T (pt) 2024-04-23
EP4342542A3 (en) 2024-06-05
CN110662540A (zh) 2020-01-07
RS65488B1 (sr) 2024-05-31
LT3630112T (lt) 2024-05-10
BR112019025478A8 (pt) 2022-12-06
JP7475402B2 (ja) 2024-04-26
EP3630112B9 (en) 2024-06-26
PE20200859A1 (es) 2020-08-25
JP2022169780A (ja) 2022-11-09
HRP20240551T1 (hr) 2024-07-05
RS65488B9 (sr) 2024-09-30
JP2024096905A (ja) 2024-07-17
AU2018276273A1 (en) 2019-12-12
WO2018219807A1 (en) 2018-12-06
CA3065125A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
EP2900269B1 (en) Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
JP7475402B2 (ja) 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
HK40015063B (zh) 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
HK40015063A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
BR122025015903A2 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2), seu uso, e kit para tratamento de distúrbios hiperproliferativos

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601